Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

paresh_vyas

Prof Paresh Vyas has just been awarded a Grant from Leukaemia and Lymphoma Research  - A first-in-human, first-in-class Phase I dose escalation trial of Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Acute Myeloid Leukaemia (AML).

Paresh says – “Leukaemia and Lymphoma Research is one of the biggest charitable funders of haematology research in the UK.  They have awarded the MRC Molecular Haematology Unit a grant of £300 000 to conduct a first-in-class first in man clinical trial of a novel immunotherapeutic monoclonal antibody, directed against the cell surface protein CD47, to treat patients with relapsed/refractory Acute Myeloid Leukaemia.  This is an innovative therapeutic that aims to harness the body’s own immune system to fight cancer.  The work is a an exciting collaboration with the Oxford Early Phase Oncology Clinical Trials Unit, Stanford University and the UK AML Clinical Trials Group.“

Similar stories

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.

2022 RDM Graduate Prize Winners

This year's RDM winners are Edward Jenkins, Antje Rottner, and Akshay Shah.

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing

The biotechnology company builds upon research conducted by Professor Jim Hughes and Prof. James Davies at the MRC Weatherall Institute of Molecular Medicine, and combines 3D genome technology and machine learning to decode the dark matter of the human genome.

KJ Patel appointed new Chief Scientist of CRUK

Alongside his new role at Cancer Research UK, Prof. Patel will continue as the Director of both the MRC Weatherall Institute for Molecular Medicine (MRC WIMM) and the MRC Molecular Haematology Unit (MRC MHU).

September is Childhood Cancer Awareness Month

September is Childhood Cancer Awareness Month, where our Childhood Leukaemia research group have taken action to help raise awareness for this cause.